The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
The Medical Treatment of Cushing’s Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery
Open accessAbstract
BACKGROUND: The role of dopamine agonists in the treatment of Cushing's disease (CD) has been previously debated. AIM: The aim of this study was to evaluate the effectiveness of short-term (3 months) and long-term (12-24 months) treatment with cabergoline in patients with CD. PATIENTS AND METHODS: 20 patients with CD unsuccessfully treated by surgery entered the study. Cabergoline was administered at an initial dose of 1 mg/wk, with a monthly increase of 1 mg, until urinary cortisol levels normalized or the maximal dose of 7 mg/wk was achieved. The responsiveness to treatment was evaluated according to changes in urinary cortisol excretion. A decrease greater than 25% was considered as a partial response, whereas complete normalization was considered as a full response at short-term evaluation; persistence of normal cortisol excretion was the only criterion to evaluate the response at long-term evaluation. RESULTS: After short-term treatment, 15 (75%) patients were responsive to cabergoline treatment. Among these, normalization of cortisol excretion was maintained in 10, whereas treatment escape was observed in five patients after 6-18 months. Among the 10 long-term responsive patients, eight were followed for 24 months, whereas the remaining two were followed for 12-18 months, due to cabergoline withdrawal for intolerance. A sustained control of cortisol secretion for 24 month cabergoline treatment at the maximal dose ranging from 1-7 mg/wk (median: 3.5) without significant side effects, was obtained in eight of 20 (40%) patients. CONCLUSIONS: The results of this study demonstrated that cabergoline treatment is effective in controlling cortisol secretion for at least 1-2 yr in more than one third of a limited population of patients with CD. If this evidence is confirmed by additional studies, this agent may be considered as a useful treatment option in patients with CD who are unsuccessfully treated by neurosurgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement
Biller, B. M. K., Grossman, A. B., Stewart, P. M., Melmed, S., Bertagna, X., Bertherat, J., Buchfelder, M., Colao, A., Hermus, A. R., Hofland, L. J., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2734 · Cited by 853
Self-citationDopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
Dopamine Agonists and Pituitary Tumor Shrinkage
BEVAN, J. S., WEBSTER, J., Burke, C. W., & Scanlon, M. F. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-2-220 · Cited by 469
Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Kros, J. M., Del Basso De Caro, M. L., Arvigo, M., Annunziato, L., Lombardi, G., Colao, A., Hofland, L. J., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030837 · Cited by 271
Self-citationBromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl, H., Ohashi, S., Matsuda, M., Miyazaki, Y., Mahankali, A., Kumar, V, Pipek, R., Iozzo, P., Lancaster, J. L., Cincotta, A. H., et al. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1154 · Cited by 238
The Medical Treatment of Cushing's Syndrome
MILLER, J. W., & CRAPO, L. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-4-443 · Cited by 202
Pivonello, R., De Martino, M. C., De Leo, M., Lombardi, G., & Colao, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.010 · Cited by 195
Self-citationThe Metabolic Syndrome and Cardiovascular Risk in Cushing's Syndrome
Pivonello, R., Faggiano, A., Lombardi, G., & Colao, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.010 · Cited by 173
Self-citationLamberts, S. W. J., Klijn, J. G. M., Quijada, M. D., TIMMERMANS, H. A. T., UITTERLINDEN, P., de Jong, F. H., & Birkenhäger, J. C. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-2-307 · Cited by 128
Self-citationCasulari, L. A., Naves, L. A., de Mello, P. A., Neto, A. P., & Papadia, C. (2004) · Hormone Research in Paediatrics · doi:10.1159/000082235 · Cited by 72
Dopamine: a role in the pathogenesis and treatment of hypertension
Murphy, M. B. (2000) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000987 · Cited by 66
Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline
Pivonello, R., Faggiano, A., Salle, F. D., Filippella, M., Lombardi, G., & Colao, A. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343660 · Cited by 66
Self-citationBROMOCRIPTINE IN NELSON'S SYNDROME AND CUSHING'S DISEASE
Lamberts, S. W. J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)90656-5 · Cited by 55
Self-citationACTH silent adenoma shrinking under cabergoline
Pétrossians, P., Ronci, N., Socin, H. V., Kalife, A., Stevenaert, A., Bloch, B., Tabarin, A., & Beckers, A. M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440051 · Cited by 47
Miyoshi, T., Otsuka, F., Takeda, M., Inagaki, K., Suzuki, J., Ogura, T., Date, I., Hashimoto, K., & Makino, H. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345309 · Cited by 29
Macroprolactinoma associated with Cushing’s disease, successfully treated with cabergoline
T'Sjoen, G. G., Defeyter, I. R., den Saffele, J. K. V., Rubens, R., & Vandeweghe, M. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03343983 · Cited by 24
Effect of injectable bromocriptine in patients with Cushing's disease
Invitti, C., Martin, M., Danesi, L., & Cavagnini, F. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1211361 · Cited by 23
Cited by
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953
Self-citationA 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Self-citationComplications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Self-citation
Metadata
- Authors
- Pivonello, R., De Martino, M. C., Cappabianca, P., De Leo, M., Faggiano, A., Lombardi, G., Hofland, L. J., Lamberts, S. W. J., & Colao, A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-01
- Volume
- 94
- Issue
- 1
- Pages
- 223-230
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2062122986
- Cited by
- 328
- References
- 19
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.